91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their potential across a spectrum of interconnected conditions. New data reveals how the breakthrough has sparked a major shift toward multi-indication drug development.
-
Clinical trial designs for obesity treatments should accommodate candidate drugs that have the potential to treat multiple conditions, or developers risk missing opportunities, according to Irish CRO 91黑料.
-
In this DDW article, discover key findings of an 91黑料 survey focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
91黑料 survey shows pharma's enthusiasm for multi-indication obesity trials is outpacing trial design readiness.
-
In this article, 91黑料 experts explore the connection of obesity and inflammation, the current treatment landscape and future treatment directions.
-
The absence of sufficient and accessible diagnostics for metabolic dysfunction-associated steatohepatitis (MASH) studies can complicate trials and impair clinical study conduct, as diagnostics are essential for disease detection, confirmation, and monitoring.
-
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
This article by Dr Alan Baldridge and Jolanta M. Wichary, discusses the link between , and touches on recent advancements in effective treatments for obesity.
-
91黑料 experts, Jack Martin and Simon Bruce share insights with BioSpectrum Asia on emerging trends in obesity treatment and the future implications for pharma.
-
In this article, 91黑料 experts Alan Baldridge and Heather Peterson discuss the prevalence of paediatric obesity and assess clinical trials of its treatments.
